Format

Send to

Choose Destination
Transl Oncogenomics. 2016 Feb 21;7(Suppl 1):33-49. doi: 10.4137/TOG.S30529. eCollection 2015.

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics.

Author information

1
Department of Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, London, UK.

Abstract

The phosphatidylinositol 3-kinase (PI3K) signaling pathway is integral to many essential cell processes, including cell growth, differentiation, proliferation, motility, and metabolism. Somatic mutations and genetic amplifications that result in activation of the pathway are frequently detected in cancer. This has led to the development of rationally designed therapeutics targeting key members of the pathway. Critical to the successful development of these drugs are pharmacodynamic biomarkers that aim to define the degree of target and pathway inhibition. In this review, we discuss the pharmacodynamic biomarkers that have been utilized in early-phase clinical trials of PI3K pathway inhibitors. We focus on the challenges related to development and interpretation of these assays, their optimal integration with pharmacokinetic and predictive biomarkers, and future strategies to ensure successful development of PI3K pathway inhibitors within a personalized medicine paradigm for cancer.

KEYWORDS:

PI3K; biomarkers; therapeutics

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center